About: admin

3月17日，陕西省文化和旅游厅在新加坡举行“文化陕西”旅游推介会，带着三秦大地的厚重文脉、壮美山河与真挚诚意，向狮城朋友发出最真诚的邀请。陕西省文化和旅游厅党组成员、副厅长杜金根，新加坡中国文化中心兼旅游办事处主任孔媛，新加坡全国旅行社协会出境委员会理事黄海笑出席推介会并致辞。新加坡文旅企业、新闻媒体、航空公司等代表近百人参加推介会。 杜金根表示，陕西是中华文明的重要发祥地和丝绸之路的东方起点，拥有周秦汉唐的文明根脉、雄奇秀美的自然胜境、活态传承的非遗烟火。期望与新加坡文旅业界同仁加强合作，深化客源互送，加强产品共创，推动宣传联动，促进人文互鉴。也诚邀新加坡文旅企业、艺术团体参加4月17日开幕的2026西安丝绸之路国际旅游博览会和10月份举行的丝绸之路国际艺术节，为深化双方合作开拓更多空间，注入新的发展动能。 孔媛表示，中国文化中心和旅游办事处将一如既往支持陕西与新加坡旅游业界的交流与合作，为双方搭建更多交流平台，共同推动两地旅游合作不断迈上新台阶。黄海笑表示，陕西对于新加坡人而言是家喻户晓的旅游目的地，希望推介会的成功举办能为双方带来新的合作机会，从而开发更多旅游产品，带动更多游客前往陕西旅游观光。 近年来，中国与包括新加坡在内的79个国家实施了互免或单免签证政策，全球“免签朋友圈”持续扩大。作为中国入境旅游的重要目的地，陕西抢抓免签政策带来的机遇，针对境外市场需求，积极打造精品旅游线路，不断完善双语导览、便捷支付等服务，为海外游客提供安心、舒心、暖心的旅行环境。 新加坡是陕西非常重要的入境游客源国，连续两年位居主要客源国前四位。本次“文化陕西”旅游推介会，有针对性策划了陕西旅游目的地推介、陕西旅游线路推介与东方航空航线推介等环节，再配合现场精心搭建的陕西图片展、非遗展，让参会的新加坡文旅业界代表直观了解陕西文旅资源禀赋，充分感受陕西文旅人期待开展更多合作的满满诚意。 推介会上陕西中旅、西安康辉、陕西友联三家旅行社就游客互送，产品打造、线路开发等内容，与新加坡旅行社签署了合作协议。在新加坡期间，陕西省文化和旅游厅还与新加坡中国文化中心、中国驻新加坡旅游办事处开展交流，与新加坡全国旅行社协会、新加坡超级旅游集团、新星旅游集团等旅游机构、企业座谈，推介陕西文旅产品，宣讲陕西入境游政策，推动合作落地见效。

SINGAPORE – March 18, 2026 – (SeaPRwire) – AdsDrama, a digital platform focused on short drama content and online advertising, has introduced an ecosystem designed to integrate content distribution, advertising services, and user participation. The launch comes as short-form video continues to expand globally, shaping how content is consumed and monetized across digital channels. What Is AdsDrama? AdsDrama (https://www.adsdrama.com) is a platform centered on short drama marketing and digital advertising monetization. It connects content creators, advertisers, and users through a structured system intended to support content distribution and advertising delivery. Unlike traditional content platforms where users primarily consume media, AdsDrama incorporates a participation-based model. Users can engage with certain platform functions related to content promotion and advertising processes. The platform operates through a structured framework designed to simplify user access and participation. User Onboarding New users can register and access an introductory interface that presents the platform’s core features, including its advertising workflows and operational structure. This step is intended to provide a general understanding of how the platform functions. Participation Through Structured Levels After onboarding, users may choose to access different participation levels. Each level provides access to specific platform features, which may include: Defined activity parameters Access to advertising-related tasks System-based allocation of activities The platform indicates that certain processes are managed through internal systems that handle distribution and performance tracking. Automated Advertising System AdsDrama utilizes a data-driven system to distribute short drama content across various digital channels, including: Social media platforms Short video networks Other online content distribution channels The platform states that it applies audience targeting and traffic allocation tools to support content visibility. Revenue Model According to AdsDrama, the platform incorporates multiple revenue streams as part of its business model: Online advertising revenue derived from ad placements and traffic distribution Content monetization, including paid access to selected short drama content Brand collaborations, such as sponsored content and integrations IP commercialization through licensing and content expansion Technology services related to advertising delivery and data optimization The company states that this diversified structure is intended to support ongoing platform development. Key Features of AdsDrama Data-Driven Optimization AdsDrama reports that it uses analytics and performance tracking tools to monitor advertising campaigns and refine delivery strategies. Structured Financial System The platform describes a multi-layer account system designed to manage user balances, which may include: Available balances Processing stages Pending allocations This structure is intended to support internal accounting processes and system organization. Standardized Withdrawal Mechanism AdsDrama indicates that it applies standardized procedures for withdrawals within its operational framework, aiming to streamline processing and reduce administrative complexity. Why AdsDrama Is Growing Industry trends may help explain the emergence of platforms such as AdsDrama: Growth of short-form content, as short video and serialized formats continue to attract broad audiences Expansion of digital advertising, with businesses increasing spending on online channels Gradual shift toward participation-based models, where users engage beyond passive content consumption Is AdsDrama Worth Exploring? AdsDrama may be relevant to individuals and organizations interested in: Digital advertising platforms Content distribution models Emerging forms of online engagement As with any platform, users are encouraged to review publicly available information and consider potential risks before engaging. AdsDrama represents an approach that combines short-form content with digital advertising infrastructure and user-facing features. As the digital media landscape continues to evolve, platforms of this kind reflect ongoing experimentation in content distribution and monetization models. Media contact Brand: AdsDrama LTD Contact: Media team Website: https://www.adsdrama.com

Cyprus, EU, Mar 16, 2026 - March 16, 2026 - (SeaPRwire) - FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor's approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client's internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner's IBAN account infrastructure. During the second week the team activated card issuing and configured the platform's connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective "The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. "Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website:  https://www.finharbor.com/

Cyprus, EU, Mar 16, 2026 - March 16, 2026 - (SeaPRwire) - FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor's approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client's internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner's IBAN account infrastructure. During the second week the team activated card issuing and configured the platform's connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective "The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. "Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website:  https://www.finharbor.com/

Nicosia, Cyprus – March 17, 2026 – (SeaPRwire) – FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor’s approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client’s internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner’s IBAN account infrastructure. During the second week the team activated card issuing and configured the platform’s connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective “The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. “Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website:  https://www.finharbor.com/

The Singapore-headquartered platform helps brands improve content reach and conversion in the era of short-form video and interest-based e-commerce. SINGAPORE – March 16, 2026 – (SeaPRwire) – As short-form video continues to reshape how information spreads and how consumers engage with brands, efficient collaboration between brands and creators has become increasingly important. Hello IP was built to address this need. Hello IP is a content distribution platform focused on social and interest-based e-commerce. By enabling brands to upload ready-made video content and distribute it through local creators across social platforms, Hello IP helps reduce the complexity of traditional creator collaborations, improve campaign efficiency, and create more sustainable monetization opportunities for creators. Under traditional creator marketing models, brands often face lengthy workflows that include influencer sourcing, repeated negotiation, contract signing, sample shipping, content review, and payment settlement. These processes can be slow, costly, and difficult to manage, especially in cross-border campaigns where shipping risks, inconsistent content quality, and uncertain outcomes remain common challenges. Hello IP offers a more efficient alternative. After brands upload content to the platform, creators can select tasks that match their style, audience, and interests, then distribute that content through their own channels. This model helps brands gain more localized and authentic exposure while allowing creators to earn performance-based rewards. To support faster market expansion, Hello IP has developed its core distribution system, Viral Engine, which combines creator distribution, influencer collaboration, advertising support, and cross-market strategies. The platform is currently active in mature TikTok e-commerce markets across Southeast Asia, the United Kingdom, and the United States, with content able to reach targeted creator communities in as little as 24 hours. For creators, Hello IP provides access to daily brand campaigns across categories such as beauty, mobile apps, e-commerce, and gaming. By lowering collaboration barriers and simplifying campaign participation, the platform helps creators unlock more stable income opportunities and build long-term commercial value. Mao Jianfeng, Founder of Hello IP, said, “In today’s creator economy, brands need content distribution models that are more efficient, scalable, and closely connected to local markets. Hello IP aims to build a smoother connection between brands and creators so that both sides can grow together.” As digital marketing enters a new phase, Hello IP’s connector model is creating a more efficient and inclusive path forward for the content ecosystem. About Hello IP Hello IP is one of ET CUBE’s core business pillars in the creator economy, focused on content distribution for social and interest-based e-commerce. Headquartered in Singapore, the platform connects brand content with local creator networks to help brands achieve faster, more authentic distribution and stronger conversion opportunities across key international markets. Media Contact Brand Name: Hello IP Website: https://www.helloipmcn.com

Tashkent, Uzbekistan – March 16, 2026 – (SeaPRwire) – FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor’s approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client’s internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner’s IBAN account infrastructure. During the second week the team activated card issuing and configured the platform’s connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective “The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. “Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website:  https://www.finharbor.com/

SHENZHEN, CHINA, Mar 13, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients. The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance. More information about Desidustat Tablets and Renal Anaemia As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders. There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia. Desidustat Tablets have been approved for marketing in India. CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020. The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6 2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015 3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025) 4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012 CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Mar 13, 2026 – (ACN Newswire via SeaPRwire.com) – On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order. As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients. The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026). Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster. As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2]. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval. The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. China Insights Consultancy’s industrial report  2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.  3. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 4. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Singapore – March 11, 2026 – (SeaPRwire) – HYVE Promo today announced the launch of its AI-enabled print-on-demand platform designed to modernize Asia-Pacific’s corporate gifting and branded merchandise industry. While e-commerce in Asia has produced multi-billion-dollar unicorns, the region’s corporate gifting supply chain remains largely manual — dependent on spreadsheets, fragmented factory coordination, and week-long quote cycles. HYVE enters the market as a technology-first infrastructure platform built to streamline customization, printing, and cross-border fulfillment at scale. HYVE positions itself as the corporate gifting equivalent of Asia’s major e-commerce platforms — purpose-built for businesses that need fast, reliable, and compliant branded merchandise delivered across multiple markets. “Asia built some of the world’s largest e-commerce engines,” said Tim Ngiam, General Manager of HYVE. “But the corporate merchandise industry hasn’t kept pace. We built HYVE to bring platform thinking, AI-driven workflows, and print-on-demand efficiency to a sector still operating like it’s 2005.” AI-Driven Merch Infrastructure HYVE combines: AI-assisted artwork processing and print optimization Real-time production routing across decoration technologies Automated order batching for small and mid-sized runs Cross-border logistics orchestration for APAC distribution The platform integrates directly with HYVE’s high-capacity production hub in Ningbo, China, capable of processing approximately 500 orders daily. Small-batch corporate orders can ship in as little as 72 hours, serving markets including Singapore, Japan, Korea, India, Southeast Asia, and Greater China. Rather than operating as a marketplace aggregator, HYVE controls the full print-to-ship workflow — reducing supplier handoffs and production errors. Targeting a Rapidly Digitizing Market The global promotional products market is projected to reach US$37 billion by 2033, while Asia-Pacific corporate gifting is expected to exceed US$400 billion within the same timeframe. More than 40% of buyers now expect to manage merchandise orders digitally — from proofing to tracking to fulfillment. HYVE aims to become what its founders call “Asia’s largest merch engine” — a centralized infrastructure layer for corporate gifting across the region. “Marketers and procurement teams want the same simplicity they get when ordering consumer products online,” said Ethan Ung, Co-Founder and Chief Commercial Officer. “They don’t want to manage factories, chase quotes, or coordinate customs. They want speed, visibility, and certainty. That’s what a platform should provide.” Built for Enterprise and Regional Scale HYVE focuses initially on APAC enterprise buyers and distributors, offering: On-demand production Regional multi-country fulfillment Compliance-ready manufacturing standards Rapid turnaround for campaign-driven activations The company plans to expand product categories, introduce deeper AI automation across artwork and routing, and integrate with marketing and e-commerce ecosystems used by enterprise teams. About HYVE Promo HYVE Promo is a Singapore-based technology platform modernizing corporate gifting across Asia-Pacific. Backed by the founders of BrandCharger and Headwind Group, HYVE operates a vertically integrated print and fulfillment engine designed to bring AI-driven efficiency, transparency, and scalability to branded merchandise distribution. For more information, visit: https://hyve.promo Media Contact Ming Yi Lim, Marketing Manager HYVE Promo Pte Ltd mingyi.lim@hyve.promo

Recently, a storm triggered by skyrocketing oil prices has swept across Asian equity markets. Major indices have suffered significant setbacks; notably, the Straits Times Index (STI) plunged 1.89% this Monday, as panic gripped the market. In such turbulent times, how does Professor Henry Ng, head of SLGM • Global Business Academy, decipher the market’s pulse and formulate rational trading strategies for his students? I. The Core of the Storm: Why Oil Price Surges Shake Asian Markets The root cause of this Asian market crash lies in the sharp rise in oil prices triggered by tensions in the Strait of Hormuz. This critical waterway handles approximately 20% of global crude oil shipments. As the region with the highest dependence on petroleum imports, Asia’s oil and gas trade deficit accounts for 2.1% of its GDP—far exceeding the Eurozone’s 1.5% and the United States’ 0.04%. Should shipping through the strait be obstructed, the energy supply for Asian economies will face immense challenges. Since the beginning of 2026, international oil prices have behaved like a "bolting horse." Brent crude futures have surged from $85 per barrel at the start of the year to over $120 today—an increase of more than 40%. This spike is not accidental; it is the result of multiple converging factors: Geopolitical Conflicts: Tensions in Middle Eastern oil-producing regions have heightened expectations of supply contraction. Demand Rebound: During the global economic recovery, energy demand has bounced back beyond expectations, widening the supply-demand gap. Macro Factors: A weakening U.S. Dollar Index and speculative capital maneuvering have collectively propelled oil prices into a new upward cycle. II. Through the Fog: Key Signals in the Current Market Significant Sector Divergence: Amidst the market sell-off, a clear divergence between sectors has emerged. Oil and gas sectors across Asia have benefited from rising prices, creating favorable conditions for growth. We previously witnessed a rare "continuous rally" among several oil and gas stocks, with average gains reaching 15%. Although they have since seen some retracement, their overall performance remains relatively resilient. In contrast, Technology stocks have taken a heavy hit. Since the start of 2026, the Hang Seng Tech Index has dropped 12.45%, while U.S. tech giants such as Intel, NVIDIA, Apple, and Microsoft have recently delivered mediocre performances. This is primarily due to market skepticism regarding the sustainability of AI spending, combined with rising inflation expectations driven by oil prices, which continues to suppress tech valuations. When the "flames" of oil prices burn fiercely, Asian stock markets are the first to feel the heat. As the core engine of global economic growth, Asian economies are generally highly dependent on external energy. Japan, South Korea, and India all have oil import dependency ratios exceeding 80%, while China’s dependency is nearing 70%. Skyrocketing oil prices directly inflate production costs and squeeze profit margins. Asian enterprises, which rely on manufacturing as their backbone, are facing the dual pressure of rising raw material prices and climbing logistics costs. This has led to setbacks and declines in the Malaysian and Singaporean stock markets. This capital storm triggered by oil has plunged Asian equities into a state of panic. Investors are offloading stocks in favor of safe-haven assets like Gold and Treasury bonds. The deterioration of market sentiment has further fueled the decline, creating a vicious cycle.   III. Many SLGM • Global Business Academy students can’t help but ask: Will rising oil prices truly crush Asian stock markets? In-Depth Analysis: The Interlinked Logic Between Oil Prices and Asian Equities To answer this question, we must conduct an in-depth dissection of the interlinked logic between oil prices and Asian stock markets. Historical data reveals that the relationship between the two is not a simple negative correlation, but rather a complex, dynamic association. In the early stages of economic recovery, a moderate rise in oil prices often reflects improving demand. During such periods, expectations for corporate earnings increase, and the stock market typically embarks on a bullish trend. However, when oil prices rise too rapidly or the magnitude of the increase becomes excessive, it creates a negative impact on the economy, thereby suppressing stock market performance. The SLGM • Global Business Academy Research Department believes that the impact of rising oil prices on Asian stock markets is primarily transmitted through the following channels: III.1. The Cost Transmission Channel Rising oil prices directly increase production costs, particularly for energy-intensive industries. Aviation, Shipping, and Logistics: Fuel is one of the primary operating costs. A surge in oil prices leads directly to declining corporate profits. Chemicals, Plastics, and Rubber: Petroleum is a vital raw material. Higher oil prices drive up the cost of these materials, further inflating production expenses. If companies cannot fully pass these increased costs on to consumers through higher product prices, their profit margins will be squeezed, putting downward pressure on their stock prices. III.2. The Inflationary Channel Surging oil prices trigger significant inflationary pressure. As a critical industrial raw material and energy source, its price hike ripples through the entire supply chain, driving up the costs of various goods and services. Monetary Policy:Rising inflation rates often prompt central banks to adopt tightened monetary policies, such as raising interest rates or increasing reserve requirement ratios. Economic Impact:These measures increase financing costs for enterprises, suppress investment, and dampen consumer spending. This ultimately hinders economic growth and corporate earnings, creating a bearish outlook for the stock market. IV. SLGM • Global Business Academy’s Solution: Market Outlook & Trading Strategies IV.1. Prioritize Short-term Defense; Focus on Safe-Haven Sectors As long as geopolitical risks persist and the upward trend of oil prices remains uncertain, a defensive strategy should be adopted for short-term trading. Focus on safe-haven sectors such as Oil & Gas, Banking, and Utilities. Oil & Gas:Directly benefits from rising prices. With ongoing tensions in the Middle East, oil prices are expected to remain elevated, providing strong support for corporate earnings. Banking:Characterized by low valuations and high dividend yields, banks often demonstrate strong resilience during market volatility. Utilities:With stable demand and minimal impact from economic cycles, this sector offers investors relatively consistent returns. IV.2. Energy Transition: Embracing the Green Revolution Skyrocketing oil prices highlight the instability and high costs of traditional energy, creating massive opportunities within the energy transition sector. As the world prioritizes environmental protection and sustainable development, the new energy industry has entered a "golden age" of growth. Clean Energy:The development of solar, wind, hydro, and nuclear energy continues to expand. Companies in these fields are poised for rapid earnings growth, positioning this sector as the next major wealth frontier. IV.3. Energy Tech Innovation: Tapping into the Technology Dividend Rising oil prices will also accelerate the development of energy technology innovation. To reduce dependence on traditional energy and improve efficiency, companies worldwide are increasing their R&D investments. Innovative breakthroughs in energy-saving technologies, smart grid systems, and carbon capture and storage (CCS) are emerging rapidly. Energy-Saving Tech:Helps enterprises lower energy consumption and reduce production costs. Smart Grid Tech:Enables efficient energy distribution and utilization, enhancing the stability of the energy supply. Conclusion In summary, while rising oil prices have brought short-term shocks to Asian stock markets, the fundamental economic outlook for Asia remains unchanged. Corporate earnings continue to show resilience, and opportunities are hidden within the crisis. Investment potential abounds in New Energy, Energy Tech Innovation, and Resource sectors, while Defensive sectors provide stable returns. Students must remain rational and calm. Formulate a sound strategy by balancing risks and returns through diversification, long-term positioning, and dynamic adjustments. You can also leverage the institutional strength of SLGM • Global Business Academy to seize cross-regional market trading opportunities.

SINGAPORE – March 09, 2026 – (SeaPRwire) – AI Labs, an AI-driven crypto trading technology company backed by Academic Labs, announced the launch of an AI-assisted platform designed to help cryptocurrency traders analyze market data and respond more efficiently to changing market conditions. As automated tools and algorithmic strategies become more common in global digital asset markets, the platform integrates visual analysis, narrative data monitoring, and automated trade execution features intended to support more structured and data-driven trading decisions. The fastest traders in today’s crypto markets may not always be humans. As digital asset markets increasingly incorporate automation, many traders now rely on algorithmic systems that can monitor markets continuously and react to signals with minimal delay. A crypto project called AI Labs (ticker: AIX) is building an AI-enabled platform that combines visual reasoning, narrative intelligence, and automated execution to help users interpret market data and respond to signals more efficiently than traditional manual analysis alone. “Markets are entering an era where the use of artificial intelligence is becoming more common in trading strategies,” said Kingston Kwek, owner of AI Labs. “Our goal is to make analytical tools that are often used by institutional trading teams more accessible to a wider group of crypto traders.” At the center of AI Labs’ platform is a visual reasoning engine that analyzes charts not simply as static images, but as evolving market structures. Using computer vision and multimodal AI techniques, the system can identify potential liquidity zones, resistance levels, and broader market patterns within short timeframes. Alongside this, AI Labs has developed a narrative intelligence layer that scans information across the crypto ecosystem. This includes movements associated with large crypto wallets, developer updates, and shifts in online sentiment—signals that traders often monitor when assessing possible market trends. Instead of only placing individual buy or sell orders, traders can define broader trading parameters using the AI system. The platform can then execute trades automatically based on predefined conditions, such as capital inflows, volatility changes, or funding-rate shifts. The objective is to help reduce emotional decision-making and allow traders to stay aligned with their strategies while automated systems monitor market activity continuously. AI Labs’ platform is currently onboarding new users, with reported monthly trading activity exceeding $1 billion across the platform. Media Contact Brand: AI Labs (Backed by Academic Labs) Contact: Media team Email: ryan@academic-labs.org Website: https://academic-labs.org

SHENZHEN, CHINA, Mar 5, 2026 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals. About CMS-D008 CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases. Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles. CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options. The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564. 2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23 3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z 4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Singapore – March 05, 2026 – (SeaPRwire) – Core Concepts Physio, one of Singapore’s leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain. Plantar fasciitis remains one of the most common and persistent causes of heel pain among adults, especially those with active lifestyles or occupations involving long hours on their feet. Often treatment seeks to address only one aspect of the condition rather than the full movement chain, which leads to recurring pain as other aspects remain unresolved. To bridge this gap, the two clinics have formalised a joint assessment pathway that evaluates plantar fasciitis from both the top-down (physiotherapy) and the bottom-up (podiatry) so as to ensure that no contributing factor is overlooked. A Smarter, More Complete Way to Diagnose Heel Pain Physiotherapy and podiatry traditionally manage different elements of plantar fasciitis. Physiotherapists focus on mobility, strength, gait and load tolerance, while podiatrists address foot posture, footwear, ground forces and orthotic support. The new integrated pathway combines both perspectives into a single, coordinated evaluation which results in: More accurate, holistic diagnoses Fully optimised treatment strategies Fewer flare-ups and recurrences Clearer, consistent guidance for patients Faster and more sustainable outcomes “Many patients struggle because plantar fasciitis isn’t caused by just one issue,” said Mr Chng Chye Tuan, Senior Principal Physiotherapist at Core Concepts Physiotherapy. “It’s a movement chain problem involving the foot, calf, ankle mobility, daily load and footwear. When physiotherapists and podiatrists work together, we address every contributing factor — not just the symptoms.” A Case Study Demonstrating Collaborative Success In a recent case, a 42-year-old recreational runner sought help after six months of persistent heel pain. Physiotherapy improved his morning pain and running tolerance, but he continued to experience flare-ups following long work shifts. A podiatry assessment revealed prolonged pronation, footwear-related loading issues and inadequate shock absorption. With customised orthoses and tailored footwear recommendations, the patient’s daily load decreased significantly — allowing physiotherapy progress to continue without setbacks. Within 10 weeks of coordinated care, he achieved pain-free mornings, comfortable workdays and full return to running. “This case reflects what we see frequently,” said Mr Yeo Boon Kiak, Principal Podiatrist at Podiatry Quest. “Physiotherapy builds tissue capacity, strength and movement control. Podiatry reduces unnecessary strain and optimises how forces enter the foot. When combined, this creates the ideal environment for long-lasting recovery.” Making Multidisciplinary Care Accessible Nationwide Through this collaboration, patients with plantar fasciitis now benefit from: Joint physiotherapy–podiatry assessments Aligned clinical decision-making Consistent communication across providers A thorough evaluation of both the cause and consequence of heel pain A fully optimised recovery pathway “Our multidisciplinary team brings together the best of both professions,” said Mr Chng Chye Tuan. “Whether someone is a runner, a frequent traveller or stands long hours at work, this collaboration ensures their care is comprehensive, precise and built around their real-life demands.” About Core Concepts Physiotherapy Core Concepts Physio is one of Singapore’s largest private physiotherapy groups, offering evidence-based musculoskeletal and sports physiotherapy across multiple clinic locations. Their multidisciplinary approach allows clients to benefit from integrated care, ensuring complete and effective recovery. Know more please contact marketing@coreconcepts.com.sg or call +65 62263632 or visit our office at 6 Raffles Quay, #11-01, Singapore 048580. About Podiatry Quest Podiatry Quest specialises in diagnosing and treating foot, ankle and lower limb conditions. Led by experienced podiatrists, the clinic offers services such as customised orthoses, biomechanical assessments, gait analysis and comprehensive podiatric care. Contact Details Organization: Core Concepts Pte Ltd Contact: Clemence Lim Email: marketing@coreconcepts.com.sg Website: https://www.coreconceptsphysio.sg

On February 27, the seminar themed “Technology Diffusion and Asia Prosperity” was held in Singapore. The event was hosted by Singapore-based consultancy Edge Research and marked the launch of its “Asia Prosperity Initiative.” Experts and representatives from policymaking, academia, and industry gathered to engage in in-depth discussions on trends in AI technology diffusion, the development of AI agents, and the future of regional AI governance. Technology Diffusion Drives Social Transformation; Youth Development Pathways Being Rewritten During the roundtable session on “How Responsible Technology Diffusion can enable a Prosperous Asia”, participants focused on the impact of AI development on employment structures, education systems, and talent cultivation models. Professor Lawrence LOH, Director of Centre for Governance and Sustainability at the National University of Singapore Business School, noted that the main arena of frontier technological innovation has gradually shifted from traditional universities to corporations. Technology companies such as Google in the United States, Alibaba and Tencent in China have become key engines of AI innovation. Drawing on his teaching observations, he pointed out that certain job positions are facing displacement pressure from AI, intensifying competition for university graduates. How education systems can cultivate new types of talent suited to the AI era has become an urgent and practical question. ZHANG Fan, Founder of Edge Research, cited U.S. studies indicating that generative AI has a greater impact on entry-level positions than on mid- to senior-level roles. In this context, companies will play an increasingly critical role in talent training and workplace adaptability. He referenced the example of U.S. tech company Palantir directly recruiting high school graduates for systematic training, describing it as an innovative exploration beyond traditional academic pathways and a new approach to diversified talent development. Rapid Deployment of AI Agents; Heightened Security and Accountability Challenges During the roundtable session on “AI for Good and Development in Southeast Asia”, discussions shifted toward the development and governance of AI agents. Alvin CHIA, Head of APAC Digital Asset Innovation at Northern Trust, observed from the financial sector perspective that AI agents demonstrate significant efficiency advantages in areas such as customer service automation, risk management assistance, and trading decision support. However, the high sensitivity of financial systems necessitates extreme caution in deploying AI agents. “Each new tool integrated into an AI agent adds a potential attack surface,” he noted. Unauthorized agent operations may trigger compliance risks and financial fraud issues, making standardized protocols and cybersecurity mechanisms particularly critical. HUANG Jingyang, Assistant Professor at the School of Public Policy, The Chinese University of Hong Kong (Shenzhen), highlighted that some AI hardware and agents currently achieve cross-application operations through underlying permissions such as screen reading and simulated clicks. Originally designed to assist visually impaired users, such technologies in commercial applications may lead to excessive privacy concessions and data misuse risks, while also disrupting existing internet business models. In contrast, cross-application collaboration mechanisms based on protocols such as A2A (Agent-to-Agent) and MCP, though still requiring user experience optimization in the short term, offer greater robustness in terms of privacy protection and ecosystem sustainability. WANG Yin, Assistant Professor of Accounting at Singapore Management University, emphasized that the “black-box” decision-making nature of AI agents complicates accountability. When system decisions go wrong, it remains unclear whether responsibility should lie with developers, deployers, end users or other possible stakeholders. No country has yet provided a definitive answer. Therefore, defining authorization boundaries and establishing traceable accountability mechanisms will be central issues in designing AI agent governance frameworks. ZHANG Fan added that AI agents are akin to “butlers”. If individuals hand over even the keys to their bedrooms or safes to AI agents, personal privacy and security are inevitably at risk. From this perspective, AI agent applications must strike a balance among convenience, reliability, and security. Ongoing Governance Exploration; Promising Prospects for Southeast Asia Participants also exchanged views on global AI governance trends and Southeast Asia’s regional development trajectory. Benjamin GOH, Senior Assistant Director at Singapore’s National AI Group, remarked that the European Union’s AI Act, as an early mover in comprehensive AI regulation, has exerted significant influence on global AI governance debates. Meanwhile, Asian countries are actively exploring governance pathways suited to their respective development stages. The recently held India AI Impact Summit put forward proposals on issues such as data sharing and management. This January, Singapore’s Infocomm Media Development Authority (IMDA) released the Model AI Governance Framework for Agentic AI, aiming to provide a reference framework for industry and promote international dialogue. WANG Yin stressed that at the governmental level, differences in institutional capacity across Southeast Asian countries must be acknowledged. Beyond regulation, effective implementation and policy execution deserve equal attention. HUANG Jingyang added that from an industry perspective, self-regulation and consensus on standards are particularly important. Before hard regulations are introduced, industries are often the first to identify emerging risks; therefore, establishing voluntary standards within the sector is essential to advancing effective governance. Regarding AI development prospects in Asia, particularly Southeast Asia, participants expressed optimism. Although Southeast Asian countries may follow in foundational large-model capabilities, they possess distinct strengths in application-layer innovation. With advantages in population scale, market diversity, and geostrategic positioning, Southeast Asia is well-positioned to build upon high-quality global foundation models, advance deep localization and adaptation, accelerate inclusive AI applications across sectors, and drive the regional digital economy toward a more inclusive growth trajectory.